Adjuvant Therapy of Colon Cancer: Current Status and Future Developments
- 1 August 2005
- journal article
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
- Vol. 18 (03) , 224-231
Abstract
Options for the adjuvant therapy of resected stage III colon cancer have expanded beyond the previously well-accepted standard of 5-fluorouracil (5-FU) combined with leucovorin. The Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer. This study, in addition to National Surgical Adjuvant Breast and Bowel Project (NSABP) C-06, which demonstrated the equivalence of tegafur-uracil (UFT)/leucovorin with 5-FU/leucovorin, provides support for use of oral fluoropyrimidines for adjuvant therapy. Support for use of multiagent chemotherapy has been provided by the European MOSAIC study, which demonstrated a significant improvement in 3-year disease-free survival for the addition of oxaliplatin (Eloxatin) to infusional 5-FU and leucovorin (FOLFOX). Although adding irinotecan (Camptosar) to a bolus 5-FU and leucovorin regimen did not improve outcome in the adjuvant setting, the PETACC studies are evaluating the combination of infusional 5-FU, leucovorin, and irinotecan. In contrast to agreement on the appropriateness of therapy for stage III colon cancer, adjuvant therapy for patients with stage II disease remains controversial. Future advances in adjuvant therapy may include targeted therapies. Based on data demonstrating efficacy for the monoclonal antibodies bevacizumab (Avastin) and cetuximab (Erbitux) in the metastatic setting, clinical trials adding these agents to standard chemotherapy have been initiated in the adjuvant setting. Specifically, one U.S. cooperative group trial will evaluate the addition of bevacizumab to chemotherapy, a second will assess the addition of cetuximab, and a third trial will evaluate FOLFOX, infusional 5-FU/leucovorin (FOLFIRI), and FOLFOX followed by FOLFIRI. Finally, a study for patients with stage II disease and adverse prognostic factors will open. An important consideration in the new clinical trials is an assessment of molecular markers that either predict response or resistance to therapy or provide other prognostic information.Keywords
This publication has 37 references indexed in Scilit:
- Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site GroupJournal of Clinical Oncology, 2004
- Randomized Trial of Adjuvant Therapy in Colon Carcinoma: 10-Year Results of NSABP Protocol C-01JNCI: Journal of the National Cancer Institute, 2004
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004
- Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized TrialsJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2001
- Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trialThe Lancet, 1999
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990